生物制药公司Galapagos NV（股票代码：GLPG）在周四盘前交易中股价大幅下跌13.49%，主要原因是该公司公布的季度业绩远低于市场预期，引发投资者对公司未来发展的担忧。
根据公司最新发布的财报，截至6月30日的季度，Galapagos NV调整后每股亏损1.60欧元，远低于分析师平均预期的每股亏损0.20欧元。相比之下，去年同期该公司还实现了每股0.14美元的盈利。此外，公司季度营收同比下降16.2%，降至6529万欧元，也未达到分析师预期的7060万欧元。
这一糟糕的业绩表现引发了投资者的担忧。值得注意的是，过去三个月中，分析师已经大幅下调了对Galapagos NV的盈利预测，平均预期下降了约1516%。目前，华尔街分析师对该公司的12个月目标价中位数为24.50美元，较其上一交易日收盘价33.29美元低约35.9%，反映出市场对公司未来表现的信心不足。这些因素共同导致了Galapagos NV股价的大幅下跌，抹去了该股今年以来19.2%的涨幅。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.